Seaport Therapeutics, Inc.
No financial data available for SPTX.
Company may not file with SEC or CIK is unresolved.
Seaport Therapeutics reports Q1 2026 results with clinical progress on GlyphAgo and GlyphAllo programs, raises $260M in IPO with cash runway into 2029
“The first quarter of 2026 was filled with meaningful progress for Seaport, and we significantly advanced the clinical development of our lead GlyphAllo and GlyphAgo programs.”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | 2026-05-04 | ARCH Venture Partners XII, LLC | 10% Owner | Purchase | 1.10M | $18.00 | $19.80M | 6.29M | View |
Informational purposes only, not investment advice.